Chalcogen Or Nitrogen Bonded Directly To The Hetero Ring Patents (Class 514/470)
  • Patent number: 10973775
    Abstract: Bacteria-responsive core-shell nanofibers and a process for the preparation thereof are described. The nanofibers release of an antibacterial agent in response to the presence of bacteria. The core of the nanofiber comprises a biocompatible polymer together with an antibacterial agent such as a quaternary ammonium compound, for example benzyl dimethyl tetradecyl ammonium chloride (BTAC). Surrounding the core is shell comprised of a bacterially degradable polymer, which is susceptible to break-down by bacterial enzymes such as lipase, or to acidic pH conditions. The shell may comprise, for example, polycaprolactone (PCL) and poly(ethylene succinate) (PES). The nanofibers may be incorporated into wound dressings.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: April 13, 2021
    Assignee: UNIVERSITY OF MANITOBA
    Inventors: Song Liu, Sarvesh Logsetty
  • Patent number: 10913748
    Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof and methods of using the same for treating cardiovascular diseases.
    Type: Grant
    Filed: October 12, 2019
    Date of Patent: February 9, 2021
    Assignee: Coeurative, Inc.
    Inventor: John Frederick Schmedtje, Jr.
  • Patent number: 10682335
    Abstract: The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the ?-amyloid protein (A?) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of A? in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: June 16, 2020
    Assignee: EVERFRONT BIOTECH INC.
    Inventors: Hong-Lin Su, Chia-Yu Chang, Shiaw-Min Hwang, Huai-En Lu, Horng-Jyh Harn, Shinn-Zong Lin, Ping-Shan Lai
  • Patent number: 10421737
    Abstract: The invention provides a new process for the preparation of optically active Beraprost of formula (I) starting from racemic Beraprost alkyl ester through hydrolysis, enantiomer esterification, preparation of diacyl-Beraprost ester diastereomers and their separation and hydrolysis.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: September 24, 2019
    Assignee: CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD.
    Inventors: Irén Hortobágyi, István Lászlófi, Zsuzsanna Kardos, József Molnár, László Takács, Tamás Bán
  • Patent number: 10335354
    Abstract: The invention provides the use of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide for the topical cosmetic treatment of the skin and of the scalp, in particular an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: July 2, 2019
    Assignee: SEDERMA
    Inventors: Olga Gracioso, Caroline Ringenbach, Thibault Marchand, Philippe Mondon, Nicolas Barriere
  • Patent number: 10287243
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 14, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9655877
    Abstract: The subject invention provides novel and advantageous materials and methods for treating neuroinflammation, neurodegenerative disease, and cerebrovascular disease by modulating TNF-? and/or nitric oxide production. Specifically exemplified herein is the therapeutic use of senkyunolide A (Sen A) and Z-ligustilide (Z-Lig), compounds isolated from traditional Chinese medicinal material Ligusticum chuanxiong (LCX).
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: May 23, 2017
    Assignees: VERSITECH LIMITED, BAGI RESEARCH LIMITED
    Inventors: Allan Sik Yin Lau, Lai Hung Cindy Yang, Cho Tsun Or
  • Patent number: 9533012
    Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: January 3, 2017
    Assignee: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Ru-Huei Fu, Shih-Ping Liu, Po-Cheng Lin, Ming-Hsi Chuang
  • Patent number: 9518251
    Abstract: A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 13, 2016
    Assignee: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Ru-Huei Fu, Shih-Ping Liu, Po-Cheng Lin, Ming-Hsi Chuang
  • Patent number: 9504751
    Abstract: A pharmaceutical composition comprising: (a) a medium system, comprising a first component, a second component and a third component, wherein the first component is a phosphate buffered saline, the second component is selected from the group consisting of vegetable oils, animal oils, fatty acids and combinations thereof, and the third component is selected from the group consisting of polyethylene glycol, dimethyl sulfoxide (DMSO), ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, 2-hydroxyethyl 12-hydroxyoctadecanoate, tocopheryl polyethylene glycol succinate and combinations thereof; and (b) n-butylidenephthalide (BP).
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 29, 2016
    Assignee: EVERFRONT BIOTECH INC.
    Inventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin, Yu-Han Chiu
  • Patent number: 9422304
    Abstract: Isohexide dicarbamates and a method of preparing the same are described. The method involves reacting a mixture of an isohexide and a cynate salt in a non-aqueous solvent, with a miscible acid having a pKa of about 3.7 or less. The isohexide dicarbamates can serve as precursor materials from which various derivative compounds can be synthesized.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 23, 2016
    Assignee: Archer Daniels Midland Company
    Inventor: Kenneth Stensrud
  • Patent number: 9416120
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • Patent number: 9358199
    Abstract: The use of one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms as thickeners is described. The use is preferably in cosmetic, dermatological or pharmaceutical compositions, in crop protection formulations, in washing or cleaning compositions or in paints or coatings.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: June 7, 2016
    Assignee: Clariant International Ltd.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl
  • Patent number: 9295626
    Abstract: What are described are compositions comprising a) one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms, and b) one or more substances selected from the group consisting of hydroxypyridones and their salts. The compositions are distinguished in particular by an advantageous antimicrobial activity.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: March 29, 2016
    Assignee: Clariant International Ltd.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
  • Patent number: 9254297
    Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 9, 2016
    Assignee: Vascular Biogenics Ltd.
    Inventors: Naamit Sher, Victor M. Young, Alyn McNaughton, Massoud Bakhshaee, Ian Robert Wilding
  • Patent number: 9233081
    Abstract: A fat-reducing agent includes a carotenoid-containing composition as an active ingredient, the carotenoid-containing composition including: a carotenoid component including at least one crystalline carotenoid, wherein at least 90% by mass of the crystalline carotenoid is in the non-crystalline state; and a (poly)glycerin fatty acid ester containing from 1 to 6 glycerin units and from 1 to 6 fatty acid units, and having at least one hydroxyl group in the glycerin units.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 12, 2016
    Assignee: FUJIFILM Corporation
    Inventors: Yuriko Oda, Fumitaka Ueda, Shinichiro Serizawa
  • Publication number: 20150148412
    Abstract: The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Applicant: MAPI PHARMA LIMITED
    Inventor: Ehud MAROM
  • Publication number: 20150139978
    Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 21, 2015
    Inventors: Ming-Jen Cheng, Ping-Hsun Yang, Ming-Der Wu, Shie-Jea Lin, Gwo-Fang Yuan, Yen-Lin Chen, Hsuen-Chun Liao, Kai-Ping Chen
  • Publication number: 20150133442
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Inventors: Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 9029412
    Abstract: Method for preparing diamino-dianhydro-dideoxyhexitols, particularly 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol. The invention related to a method for preparing diamino-dianhydro-dideoxyhexitols, particularly preferably 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: May 12, 2015
    Assignee: Evonik Degussa GmbH
    Inventors: Guido Streukens, Christian Lettmann, Sven Schneider
  • Publication number: 20150126599
    Abstract: A process is described for producing an isohexide wherein an hexitol or a combination of hexitols is continuously dehydrated in the presence of an acid catalyst under vacuum using a thin film evaporator.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Alexandra Sanborn, Brennan Smith, Joshua Terrian, Erik Hagberg, Erin Rockafellow, Kenneth Stensrud
  • Patent number: 9023817
    Abstract: A pharmaceutical composition containing albiflorin and use thereof in manufacturing medicaments for preventing and treating depression are provided by the present invention.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 5, 2015
    Inventor: Zuoguang Zhang
  • Publication number: 20150118318
    Abstract: Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder. The nanolipogel includes a lipid bilayer surrounding a hydrogel core, which may optionally include a host molecule, for example, an absorbent such as a cyclodextrin or ion-exchange resin. In preferred embodiments at least one of active agents is an immunosuppressant.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Applicant: Yale University
    Inventors: Tarek M. Fahmy, Michael Look, Joseph Craft
  • Publication number: 20150119418
    Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.
    Type: Application
    Filed: April 15, 2013
    Publication date: April 30, 2015
    Applicant: TOA EIYO LTD.
    Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
  • Publication number: 20150111962
    Abstract: Macrocycle containing carbamate compounds that inhibit HIV proteolytic enzymes and processes for preparing them are described. Compositions and methods for treating a patient infected with HIV are described.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventor: Arun K. Ghosh
  • Patent number: 9006284
    Abstract: A pharmaceutical composition of a tubulin polymerisation inhibitor and an mTOR inhibitor and a method of treating proliferative disease with a combination of a tubulin polymerisation inhibitor and an mTOR inhibitor.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: April 14, 2015
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, David Bibby, Annabell Leske
  • Publication number: 20150072958
    Abstract: Various embodiments of the present invention relate to, among other things, compounds and methods of using those compounds to treat an HIV infection. The compounds of the various embodiments of the present invention provide, among other things, therapeutic agents having enhanced penetration capability across the blood-brain barrier, such that they can enter the CNS to treat an HIV-1 infection in the CNS.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventors: Arun K. Ghosh, Hiroaki Mitsuya, Sofiya Yashchuk
  • Patent number: 8952056
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: February 10, 2015
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
  • Publication number: 20150038575
    Abstract: Melanogenesis-inhibitory constituents of Ligusticum sinense are disclosed. The melanogenesis-inhibitory constituents can be compound I, II, or III having the chemical structures as follow, respectively.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 5, 2015
    Inventor: Ching Kuo LEE
  • Publication number: 20150038576
    Abstract: A composition includes a liquid. The liquid aerosolizes for delivery to a user by an airway. The liquid includes an agent that activates a TRPV3 channel. The agent includes a terpenoid compound.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Applicant: SENTIENS, LLC
    Inventors: Inna S. Timokhina, Reid von Borstel, Dennis Tan, John Siverling
  • Publication number: 20150031760
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof, and a method of using the composition to prevent or treat nervous system disorders. Moreover, the present invention relates to a functional food composition for alleviating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition and the functional food composition can be effectively used to prevent or treat degenerative brain disorders caused by a variety of cerebral nervous system abnormalities in persons, as well as depressive disorder and anxiety.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 29, 2015
    Applicant: Research and Business Foundation SUNGKYUNKWAN UNIVERSITY
    Inventor: Choon Gon JANG
  • Publication number: 20150025068
    Abstract: A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 22, 2015
    Inventors: Jessica Martinsson, Katarina Faernegardh, Mattias Joensson, Rune Ringom
  • Publication number: 20150018371
    Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Inventors: Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
  • Publication number: 20150011623
    Abstract: The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera. More specifically, the present invention relates to a pharmaceutical composition for treating the gastrointestinal tract, the composition containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera, and to the use thereof as a therapeutic agent for gastrointestinal diseases.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 8, 2015
    Inventor: Nak Doo Kim
  • Publication number: 20150011624
    Abstract: The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 8, 2015
    Applicant: CHO DANG PHARM. CO., Ltd
    Inventor: Nak Doo Kim
  • Publication number: 20150011622
    Abstract: The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera and, more specifically, to a dosage form for treating the gastrointestinal tract, the dosage form containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 8, 2015
    Applicant: CHO DANG PHARM. CO., Ltd.
    Inventor: Nak Doo Kim
  • Patent number: 8927601
    Abstract: Provided is a method for treating a liver injury such as fibrosis, cirrhosis and hepatitis as well as a method for restoring liver function in a subject, which includes administrating to the subject a therapeutically effective amount of n-butylidenephthalide having the formula (I) as an active ingredient, or a pharmaceutically acceptable salt of ester thereof: wherein R is ?CHCH2CH2CH3, and n-butylidenephthalide (I) is E form, Z form or a mixture thereof.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: January 6, 2015
    Assignee: National Dong Hwa University
    Inventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin
  • Patent number: 8927544
    Abstract: The present invention relates to benzofuran-2-sulfonamide derivatives with the following formula: or pharmaceutically acceptable salts thereof. The derivatives are useful as modulators of chemokine receptors.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: January 6, 2015
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8921365
    Abstract: The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilization or rupture of the bacterial cell wall.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 30, 2014
    Assignee: Biomet Deutschland GmbH
    Inventor: Nicole Duewelhenke
  • Publication number: 20140378492
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: HAIQING YUAN, RICHARD L. BEARD, MICHAEL E. GARST, JOHN E. DONELLO, XIAOXIA LIU, VEENA VISWANATH
  • Publication number: 20140369943
    Abstract: What are described are compositions comprising a) one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms, and b) one or more halogenated antimicrobially active compounds. The compositions are distinguished in particular by an advantageous antibacterial activity.
    Type: Application
    Filed: July 31, 2012
    Publication date: December 18, 2014
    Applicant: CLARIANT INTERNATIONAL LTD.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
  • Publication number: 20140357555
    Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses to of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.
    Type: Application
    Filed: July 10, 2014
    Publication date: December 4, 2014
    Inventors: Ming-Jen Cheng, Ping-Hsun Yang, Ming-Der Wu, Shie-Jea Lin, Gwo-Fang Yuan, Yen-Lin Chen, Hsuen-Chun Liao, Kai-Ping Chen
  • Publication number: 20140356296
    Abstract: Described are isosorbide derivatives according to general formula wherein R and R?, independently of one another, are: (i) hydrogen atom, or (ii) radical COR?, wherein R? is linear or branched, saturated or unsaturated alkyl radical having 5 to 23 carbon atoms, or (iii) linear or branched, saturated or unsaturated alkyl radical having 6 to 22 carbon atoms, or (iv) radical CH2—CHOH—R??, wherein R?? is linear or branched alkyl radical having 6 to 22 carbon atoms, or (v) radical (CH2—CH2O)n—H and/or (CH2—CH(CH3)—O)m—H, wherein n and m, independently of one another, are an integer or fraction from 1 to 10, or (vi) for radical SO3OX, wherein X represents a sodium or ammonium ion, with the proviso that at most one of the radicals R and R? is a hydrogen atom. The isosorbide derivatives are useful as components of cosmetic compositions.
    Type: Application
    Filed: September 7, 2012
    Publication date: December 4, 2014
    Applicant: BASF SE
    Inventors: Claudia Stoer, Markus Dierker, Claus Nieendick, Werner Seipel, Ansgar Behler, Daniela Prinz, Catherine Breffa, Markus Weissenegger, Hans-Christian Raths
  • Publication number: 20140348763
    Abstract: Compositions comprising isosorbide monoesters and alcohols comprising at least one aromatic group What are described are compositions comprising a) one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms, and b) one or more alcohols comprising at least one aromatic group. The compositions are distinguished in particular by an advantageous antimicrobial activity.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 27, 2014
    Applicant: CLARIANT INTERNATIONAL LTD.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
  • Patent number: 8877804
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: November 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
  • Publication number: 20140323564
    Abstract: What are described are compositions comprising one or more compounds of the formula (I) and one or more compounds of the formula (II) in which R, Ra and Rb each independently of one another are straight-chain or branched saturated alkyl groups having 5 to 11 carbon atoms or straight-chain or branched mono- or polyunsaturated alkenyl groups having 5 to 11 carbon atoms, wherein the total amount of the compounds of the formulae (I) and (II), based on the total weight of the compositions, is at least 60% by weight. In an advantageous manner, the compositions are suitable for producing cosmetic, dermatological or pharmaceutical compositions, crop protection formulations, washing or cleaning compositions or paints or coatings.
    Type: Application
    Filed: July 31, 2012
    Publication date: October 30, 2014
    Applicant: CLARIANT INTERNATIONAL LTD.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
  • Publication number: 20140323507
    Abstract: In some embodiments, the present invention provides methods of treating a tumor in a subject. In some embodiments, the methods may include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid, an analogue thereof, or a derivative thereof; and (b) at least one anti-neoplastic agent. In some embodiments, the antineoplastic agent may include at least one of 5-fluouracil (5-FU), paclitaxel, oxaliplatin, doxorubicin, etoposide, irinotecan, bleomycin, imiquimod, 13-cis-retinoic acid, and combinations thereof. In some embodiments, the relative concentrations of the mycophenolic acid, the analogue thereof, or the derivative thereof, and the at least one anti-neoplastic agent correspond to their respective IC50 values.
    Type: Application
    Filed: September 21, 2012
    Publication date: October 30, 2014
    Applicant: Texas A & M University System
    Inventors: Robert Y. Tsai, Tao Lin
  • Publication number: 20140315996
    Abstract: The use of one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms as antimicrobially active compound is described. The use is preferably in cosmetic, dermatological or pharmaceutical compositions, in crop protection formulations, in washing or cleaning compositions or in paints or coatings.
    Type: Application
    Filed: July 31, 2012
    Publication date: October 23, 2014
    Applicant: CLARIANT INTERNATIONAL LTD.
    Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
  • Publication number: 20140309213
    Abstract: This invention relates to compounds of Formula I-VI having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH2)n1— and —(CH2)n2—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Application
    Filed: October 25, 2012
    Publication date: October 16, 2014
    Inventors: Shawn P. Walsh, Alexander Pasternak, Reynalda K. DeJesus, Haifeng Tang, Barbara Pio, Aurash Shahripour, Kevin M. Belyk, Harry R. Chobanian, Yan Guo, Jessica L. Frie, Zhi-Cai Shi, Helen Chen, Timothy A. Blizzard, Brian Cato
  • Patent number: 8853430
    Abstract: The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: October 7, 2014
    Assignee: Hetero Research Foundation
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Rapolu Raji Reddy, Bandi Vamsi Krishna, Kesireddy Subash Chander Reddy